Bayer investors unhappy over Monsanto back management, for now

Large Bayer investors said the company ’s management, including CEO Werner Baumann, should not be removed, despite widespread unhappiness with a drop in share price since its $63 billion acquisition of St. Louis-based Monsanto Co. “A hasty replacement of the CEO would only increase the risk of a break-up and therefore can’t be in the interest of long-term-oriented investors such as Union Investment,” Janne Werning, an analyst at Germany’s Union Investment, a top-20 shareholder, said in…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news